Actual evidence supports the possible involvement of GH/IGF1 in the pathogenesis of BPH and PCa also in the general population and therapeutic agents targeting the IGF1R may be beneficial in the treatment of prostate diseases. This evidence concerns the gene GH1 and benign prostatic hyperplasia.